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Introduction
Roughly 90 years of research demonstrate the relevance of dietary nutrients for mental health. Some 
of the earliest research studies on nutrients relevant to mental illness observed irritability and mood 
problems in people known to be deﬁ  cient in the B vitamins
1, as well as reported positive improvements 
in mental illness when treated with such nutrients as manganese
2,3 and nicotinic acid;
4 regardless of 
whether or not the patients could be found to be deﬁ  cient. Although interest in such studies have declined 
since the introduction of psychiatric medications in the 1950’s, recent work on folic acid (vitamin B9) 
suggests that low levels may be associated with depressive symptomatology and poor response to 
antidepressant medication.
5
Increasing evidence about the effects of trace elements on brain and behavioral functioning is appear-
ing as well. Zinc, copper, and magnesium may play an important modulatory role in controlling a 
subtype of glutamate receptor (NMDA receptor),
6 glutamate being the primary transmitter for most 
excitatory neurons in the cerebral cortex. This NMDA receptor has been implicated in various forms 
of cortical functioning;
7 therefore it appears that decreased levels of these nutrients may produce abnor-
mal NMDA activity and subsequent abnormal behavior. Given the accumulating evidence from PET 
and fMRI imaging studies showing that schizophrenia and affective disorders are associated with 
abnormal cortical activity,
8 it is logical to state that such conditions could result, at least in part, from 
abnormalities in the nutritional status of neurons. Other studies regarding the relevance of nutrients and 
schizophrenia have been conducted as well. Comparison studies have shown that 26 medication-free 
schizophrenics were found to have signiﬁ  cantly low serum iron,
9 in addition to a study in Israel where 
both the cerebrospinal ﬂ  uid and serum of people with schizophrenia were tested to be low in magne-
sium.
10 Still others have studied essential fatty acid-related membrane processes. Among 38 schizo-
phrenics and 22 controls, in the cutaneous ﬂ  ushing response to aqueous methyl nicotinate,: 83% of the 
people with schizophrenia (but only 23% of the controls) exhibited the absence of a ﬂ  ushing response, 
indicative of deﬁ  cient levels of arachidonic acid.
11 This particular study is relevant due to the fact that 
some minerals (e.g. Zinc) are thought to be rate-limiting factors in essential fatty acid conversion 
pathways.
12
High dose vitamin therapy has been studied with a number of genetic diseases. The molecular basis 
of disease arising from as many as one-third of the mutations in a gene is an increased Michaelis con-
stant, or KM (decreasing binding afﬁ  nity) of an enzyme for the vitamin-derived coenzyme or substrate, 
which in turn lowers the rate of the reaction.
13 The KM is deﬁ  ned as the concentration of ligand required 
to ﬁ  ll one-half of the ligand binding sites. Therapeutic vitamin regimens are thought to increase intra-
cellular (cofactor) concentration, thus activating a defective enzyme, which alleviates the primary defect 
and remediates the disease. The proportion of mutations in a disease gene that is responsive to high 
concentrations of a vitamin or substrate may be one-third or greater.
14,15,16
The battle to reduce the stigma associated with nutritional therapies is still very present today, ﬁ  fty 
years later. More commonly labeled “alternative medicine/therapy,” nutritional therapies are considered 
just that: an alternative, a last resort, or are not considered at all. Over the years, major medical textbooks 
have claimed that “routine prescription of vitamin preparations is indefensible, it is poor medical prac-
tice,
17 and that “multivitamins are not necessary.
18 Goodwin went so far as to say that a bias exists in 
this particular area; where “positive results are viewed with suspicion,” and “negative results are 34
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published in the best journals.”
19 One study found 
that most doctors do not feel comfortable discuss-
ing alternative therapies with their patients, despite 
the fact that 55% of patients have requested more 
information about herbal (or natural) medicine.
20 
However, despite the presence of skeptics, 
criticisms and lack of information to the public, 
natural therapies continue to be used.
We will review a number of substances and their 
potential use in psychiatry.
Essential fatty acids
Essential Fatty Acids (EFA) must be obtained 
either from diet or through supplementation. 
Premenstrual Dysphoric Disorder (PMDD) affects 
many women in varying degrees, ranging from 
only physical symptoms before the menses to 
varying degrees of irritability, anger, and depres-
sion. Ranging from mild to severe, PMDD can be 
treated with Evening Primrose Oil (EPO). EPO 
contains two essential precursors for prostaglandin 
synthesis, 70% cis-linoleic acid, and 8 to 14% 
gamma-linolenic acid. By providing the body with 
these essential fatty acids, EPO facilitates the 
synthesis of Prostaglandin E1 (PGE1); a substance 
that women with PMDD may lack in the central 
nervous system as well as in other tissue including 
the breast tissue.
21
In an open trial, 18 women with PMDD of more 
than 1 year’s duration received 8 capsules/day of 
evening primrose oil in the last half of the men-
strual cycles for 5 cycles.
22 Irritability (p  0.001), 
depression (p  0.001), anxiety (p  0.01), and 
fatigue (p  0.01) were signiﬁ  cantly less com-
pared to baseline after the ﬁ  rst cycle of treatment. 
Total PMS scores were signiﬁ  cantly improved 
(p  0.001).
A Cochran Database review concludes that 
limited evidence gives support to a hypothesis 
suggesting that the symptoms of schizophrenia 
may result from altered neuronal membrane struc-
ture and metabolism.
23 The latter are dependent on 
blood plasma levels of certain essential fatty acids 
(EFAs) and their metabolites. They found several 
studies showing that those with schizophrenia often 
have low levels of the particular EFAs necessary 
for normal nerve cell membrane metabolism. Four 
relatively small trials (total n = 204) showed low 
levels of loss to follow up and adverse effects for 
those taking essential fatty acids. Early results 
from a few trials suggest a positive effect of 
eicosapentaenoic acid (EPA) over placebo for 
scale-derived mental state outcomes. The data, 
however, was limited, making these results difﬁ  cult 
to analyze and interpret with conﬁ  dence. A single 
small study (n = 30) investigated the value of using 
EPA as sole treatment for people hospitalized for 
relapse. Results suggested that EPA could help one 
third of people avoid instigation of standard 
antipsychotic drugs for 12 weeks (RR 0.6, CI 0.4–
0.91). There were no clear effects of primrose oil 
(omega-6) EFA supplementation. Omega-3-Fatty 
acids have been used as treatment for depression,
24 
especially eicosapentaenoic acid.
25,26,27
Vitamin B6 and Magnesium
For forty years, vitamin B6 has been used in vari-
ous amounts to treat people with autism, primarily 
younger children. Several studies have shown that 
many children with autism present with low B6, 
both the activated form (42% in one study)
28 as 
well as the functional form. Some of the earliest 
studies include an open trial in which twelve of 
sixteen improved after treatment with B6, three of 
them speaking for the very ﬁ  rst time.
29 In 1978, 
Rimland, Callaway and Dreyfus conducted a 
double-blind placebo-controlled trial in which 
eleven of ﬁ  fteen children were classiﬁ  ed as better 
on B6.
30
In a survey of 4000 parents of autistic children, 
high dose pyridoxine and magnesium treatment 
(n = 318) elicited the best response.
31 For every 
parent reporting behavioral worsening with this 
treatment, 8.5 parents reported behavioral 
improvement. The next best results were with the 
acetylcholine precursor, deanol (n = 121) with 
1.8 parents reporting a favorable response com-
pared to 1 reporting a negative response. Sixteen 
autistic children previously responsive to pyridox-
ine treatment were reassessed and randomized to 
pyridoxine or placebo. Behavior deteriorated sig-
niﬁ  cantly during pyridoxine withdrawal and 11 of 
15 children behaved better when given 300 mg/day 
of pyridoxine.
32 A double blind trial involving 
60 autistic children found that 30 mg pyridox-
ine/kg/day up to doses of 1000 mg/day and mag-
nesium, 10–15 mg/kg/day, were more helpful than 
either supplement alone in relieving the symptoms 
of autism alone. Patients receiving combined treat-
ment showed a signiﬁ  cant (p = 0.02) decrease in 
homovanillic acid excretion and signiﬁ  cant clinical 
improvement.
33 A dozen other reports (with up to 35
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190 participants) since 1965 and a review of 
clinical trials
34 have reported improvements in 
autistic children with pyridoxine and often mag-
nesium supplements,
35 although the conclusions 
have been challenged.
36
Within the past ﬁ  ve years more and more stud-
ies have been conducted that include magnesium 
as part of their treatment regimen. An extensive 
study done by Rimland and Edelson of 5780 autis-
tic patients (both children and adults) was done 
where varying doses of both B6 and Magnesium 
were given. This treatment was found to show 
improvement in 47% of its subjects.
37.
Thiamine (Vitamin B1)
For anxiety, thiamine has been used successfully 
at doses of 250 mg/day to treat patients with 
anxiety disorders, including symptoms manifesting 
as chronic fatigue, insomnia, nightmares, anorexia, 
nausea and vomiting, diarrhea or constipation, 
chest and abdominal pain, depression, aggression, 
headache, diaphoresis, and fevers of unknown 
origin. Among over 200 subjects, successful 
responders had deﬁ  cient RBC transketolase which 
normalized in 73% of the subjects and led to disap-
pearance or great clinical improvement in most of 
the symptoms.
38
The National Academy of Sciences (U.S.) has 
not set a tolerable upper level for thiamine, stating 
that no adverse effects have been reported for 
thiamine. The DRI’s for thiamine for men and 
women are 1.2 and 1.1 mg/day, respectively.
39 
Thiamine is phosphorylated to form TPP, the 
cofactor used by many enzymes.
Twenty-six patients with Leigh’s disease 
responded to high intakes of thiamin, doses ranging 
from 20 to 3000 mg/day. In two sisters, lipoic acid 
(100 mg/day) plus thiamine (3000 mg/day) pro-
vided the best remediation. Leigh’s disease is 
caused by genetic defects in the pyruvate dehydro-
genase multienzyme complex (PDHC) that uses 
TPP, lipoic acid, CoA, FAD, and NADH coen-
zymes to catalyze the conversion of pyruvate to 
acetyl-CoA. The gene encoding the E1alpha 
peptide of the E1 subunit (pyruvate decarboxylase), 
which binds TPP, is located on the X-chromosome. 
Leigh’s disease is associated with lethal lactic 
acidosis, psychomotor retardation, central nervous 
system damage, ataxia, muscle ﬁ  ber atrophy, and 
developmental delay.
40 Pyruvate and lactate 
accumulate with resulting encephalomyopathy. 
Enzymes from responsive patients show a reduced 
afﬁ  nity for TPP.
41
Vitamin B6 (Pyridoxine)
One hundred and eighty-nine subjects with either 
generalized anxiety disorder, panic disorder, or 
obsessive-compulsive disorder were evaluated for 
plasma pyridoxal phosphate (PLP) levels and com-
pared with normal controls. There was no difference 
in plasma PLP levels between the anxiety disorder 
groups and normal controls. Low levels of plasma 
PLP were found in 42% of the controls. The results 
suggested that previous reports of low PLP levels 
in psychiatric patients were unlikely to be signiﬁ  cant 
in the etiology of the psychiatric disorders.
42 Critics 
of this study point out that blood levels vary last in 
most medical conditions and do not necessarily 
reﬂ  ect tissue levels or levels within the central ner-
vous system. Blood levels of neurotransmitters are 
also typically normal in psychiatric patients. 
Vitamin B6 and folic acid.
43,44,45,46,47,48 have been 
used successfully for depression. Inositol is, unof-
ﬁ  cially, a B vitamin that is found in cell membranes 
(phosphatidylinositol) where it functions closely 
with choline.
49 Inositol was equivalent to single-drug 
therapy for depression and panic disorder in one 
study and is a potential antidepressant.
50,51 One study 
found 75% of depressed patients to be magnesium 
deﬁ  cient with another 9% at borderline levels.
52 
Magnesium supplementation was helpful.
53
The Institute of Medicine has established an upper 
tolerable limit of 100 mg/day for adults for vitamin 
B6 (pyridoxine). The recommended daily intake is 
1.3 mg/day for adults. In the liver, pyridoxine and 
pyridoxal (an oxidized form) are phosphorylated by 
pyridoxal kinase to form pyridoxine-P and PLP, the 
active cofactor form. Pyridoxine-P is oxidized to PLP 
by pyridoxine oxidase. PLP is used by 112 (3%) of 
the 3870 catalogued enzymes in the ENZYME data-
base.
54 The cofactor forms a covalent linkage (Schiff 
base) with a lysyl residue in the enzyme. This inter-
nal aldimine (enzyme-PLP) is converted to an exter-
nal aldimine (substrate-PLP) when PLP is attacked 
by a substrate amino group. Gyrate atrophy of the 
choriod and the retina is an autosomal recessive 
disease leading to blindness and affecting all ages. 
It is caused by defects in ornithine aminotransfer-
ase (OAT), a PLP-dependent mitochondrial matrix 
protein that catalyzes the breakdown of ornithine 
to delta-pyrroline-5-carboxylic acid, which is then 
converted to proline. The disease is characterized 36
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by slowly progressive chorioretinal degeneration 
leading to blindness. Ornithine accumulates 10 to 
15 fold when the enzyme is defective and appears 
to be responsible for much of the gyrate atrophy.
55 
A pyridoxine responsive form of the disease exists 
in which high doses of pyridoxine (10 to 750 mg/day) 
lead to decreased ornithine accumulation and 
reduced disease severity.
The OAT activity in ﬁ  broblast extracts of a 
pyridoxine-responsive patient with the alanine-to-
valine substitution at codon 222 (Ala226 Æ Val) 
increased from 9 to 44 nmol product/mg/h when 
the concentration of PLP in the assay was increased 
to 600 micromoles/L.
56 Vitamin B6 responsive and 
non-responsive patients were shown to have dif-
ferent point mutations resulting in a single amino 
acid change in the mature enzyme.
57 OAT activity 
increased substantially more after incubation with 
PLP in responsive patients compared to non-
responsive patients. In another study, three patients 
responded to oral vitamin B6 (600 to 750 mg/day) 
with a decrease in serum ornithine and a return to 
normal of reduced concentrations of serum lysine. 
Lower doses of vitamin B6 (18–30 mg/day) 
appeared to work as well as high doses.
58 In another 
study of 9 patients with gyrate atrophy, four 
responded to pyridoxine with greater than 50% 
reductions in ornithine levels. The non-responders 
were thought to harbor more severe genetic muta-
tions. In a Japanese study of 9 patients, only one 
responded to pyridoxine, and that individual had 
a Thr181 Æ Met mutation.
59 In another Japanese 
study, one of three patients responded to pyridox-
ine (300–600mg/day) with a 60% reduction in 
serum ornithine concentrations. A Glu318 Æ Lys 
mutation of the OAT gene was found in three 
heterozygous pyridoxine responders and one 
homozygous responder. No adverse effects of 
pyridoxine treatment at doses up to 750 mg/day 
were reported.
A double blind placebo controlled cross-
over study found high doses of pyridoxine 
(= 400 mg/day) to be effective in reducing 
symptoms of tardive dyskinesia in patients with 
schizophrenia.
60 (Pyridoxine was added to the 
normal neuroleptic treatment of all 15 patients in 
the study for 4 weeks at a time, split by a one week 
washout period. Pyridoxine treatment resulted in 
improvements in both the dyskinetic movement 
and Parkinsonian subscales with return to baseline 
when pyridoxine was withdrawn An earlier pilot 
study by the same group showed signiﬁ  cant clinical 
improvement in 4 of 5 tardive dyskinesia patients 
given 100 mg/day pyridoxine on top of their usual 
treatment.
61 Three of the responders also showed 
signiﬁ  cant improvement on the Brief Psychiatric 
Rating Scale.
The double-blind study just mentioned showed 
that baseline plasma PLP levels could be raised 
from 49 nmol/L to 690 nmol/L (a more than 14 
fold increase) safely with a dose of 400 mg per day 
of pyridoxine. A rate study showed that extremely 
large doses are well absorbed and tolerated.
62 
Although dosages in the hundreds of milligrams 
have been safely applied, reports exist of neuro-
toxic effects with very high pyridoxine use. One 
review advises avoiding doses greater than 
1000 mg per day.
63 The Merck Manual reports 
toxicity effects at 2000 mg/day and suggest a safe 
level of 200 mg/day for chronic use.
Niacinamide
In mice studies, niacinamide was found to have 
properties in common with benzodiazepines and 
barbiturates.
64 The vitamin was found to possess 
hypnotic and anticonvulsant activity, inﬂ  uence 
spinal cord activity, produce muscle relaxation 
and have aggression-diminishing effects. Com-
pared with controls, patients demonstrate 
increased ﬂ  ushing, anxiety, autonomic activity, 
and temperature after 100 mg nicotinic acid 
administration, suggesting a role for nicotinic 
acid pathways that could be manipulated by 
nutritional therapies.
65 Further controlled 
research is necessary to conﬁ  rm and extend these 
pilot ﬁ  ndings.
The DRI for niacin is 16 mg niacin equivalents/d 
for men and 14 mg equivalents/d for women, 
where 1 niacin equivalent is 1 mg niacin obtained 
through the diet or the metabolism of tryptophan. 
The term niacin is often used synonymously 
with nicotinic acid. Nicotinamide, the amide 
form of nicotinic acid, is a building block for 
both nicotinamide adenine dinucleotide (NAD) 
and nicotinamide adenine dinucleotide phosphate 
(NADP) .
“It is supposed that the favorable therapeutic 
effects of nicotinamide, nicotinic acid and their 
active biological form—NAD—are realized due 
to the mechanisms of their functioning in the 
nervous system, for treating schizophrenia, epi-
lepsy and other diseases of the nervous system”.
66 
Hoffer
67 and Pauling
68 reviewed literature pertaining 37
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to the use of various forms of niacin to treat 
schizophrenia. They found several studies in which 
success was reported with niacin therapy. However, 
these conclusions have been criticized
69 for failure 
of the investigators to support their claims with 
evidence from double-blind and placebo-controlled 
studies, which are necessary to ascertain the efﬁ  -
cacy of vitamin treatment of schizophrenia.
The DRI manual enumerates various adverse 
effects of supplemental niacin use, but these effects 
are usually associated with doses of nicotinic acid 
of 1500 mg/d. It appears that nicotinamide pro-
duces fewer side effects than nicotinic acid. This 
difference could be due to study bias, however, if 
signiﬁ  cantly fewer studies with nicotinamide have 
been performed.
Vitamin B12 and Folate
Several studies have linked a folate deﬁ  ciency to 
poor response to antidepressants. One such study 
was conducted where 213 outpatients with major 
depression were given ﬂ  uoxetine for eight weeks. 
Those subjects found to have low folate levels were 
not only more severely depressed but were sig-
niﬁ  cantly less likely to respond to ﬂ  uoxetine, which 
can be applied to other antidepressant treatments 
as well.
70 Another comparative, placebo-controlled 
study was done with ﬂ  uoxetine, where in addition 
to ﬂ  uoxetine treatment 127 patients with major 
depressive disorder were given either a folate 
supplement or a placebo for ten weeks. And 
although it was determined that it worked better in 
women than in men (due to men needing a higher 
dose of folic acid in order to reduce homocysteine 
levels), 93.9% of women who received the folate 
showed a good response, in comparison to 61.1% 
of women in the placebo group.
71
Not only can folate be used to increase antide-
pressant response, it can be used in combination 
with vitamin B12 (or by itself) to combat hyper-
homocysteinemia (high homocysteine levels) and 
reduce depressive symptoms without the use of 
additional antidepressant medication. One exten-
sive study done in Finland recruited 2,313 men 
(ages 42–60) in between 1984 and 1989, and 
recorded their average folate intake until the year 
2000. Those that were below the average intake 
level (256 mcg/day) were found to have a 
signiﬁ  cantly higher risk of severe depression than 
those above the median level.
72 Several other 
studies show that many patients diagnosed with 
depression have signiﬁ  cantly lower folate levels 
than controls.
73 Both folate and B12 deﬁ  ciencies 
are marked by high levels of homocysteine, which 
are increased among depressed patients.
74
Thirty percent of patients hospitalized for 
depression were deﬁ  cient in B12,
75 and people who 
are deﬁ  cient in B12 were 2.05 times more likely 
to be severely depressed than non-deﬁ  cient sub-
jects (28).
76 One third of depressed patients had 
low folic acid levels, with treatment improving 
their depression.
77 Low serum folate and B12 
levels predicted refractory responses to antidepres-
sant medication.
78,79,80,81 The DRI for vitamin B-12 
is 2.4 μg/d for adults. Cobalamin is the precursor 
to methylcobalamin and adenosylcobalamin, the 
bioactive cofactor forms of cobalamin. The DRI 
for folic acid is 400 μg/d.
Methylenetetrahydrofolate reductase 
(NADPH), schizophrenia, rages, and 
depression
MTHFR catalyzes the conversion of 5,10-methy-
lenetetrahydrofolate to 5-methyltetrahydrofolate. 
The latter is the predominant circulatory form of 
folate and the main carbon donor for the remeth-
ylation of homocysteine to methionine. Patients 
with severe MTHFR deﬁ  ciency (0–20% residual 
activity) present in infancy or adolescence with 
developmental delay, motor and gait dysfunction, 
seizures, schizophrenic disturbances, and other 
neurologic abnormalities; they are also at risk of 
vascular complications. MTHFR mutations, 
including the 677C Æ T polymorphism, lead to 
elevated plasma homocysteine concentrations, a 
risk factor for vascular disease and possibly 
schizophrenia.
82
Two children who were found to have homo-
cystinuria after they were examined for rages and 
seizures were initially thought to have a biochem-
ical defect in the conversion of homocysteine to 
methionine. They both responded favorably to 
low-dose folic acid (0.8–3 mg/d) with a decrease 
in urinary homocystine and other improvements, 
but the beneﬁ  ts only lasted several months, at 
which time homocystine concentrations increased 
and rages resumed. In one case, double the amount 
of folate and a low-protein diet caused improve-
ment; in the other, betaine and a low-protein diet 
were effective. The authors suggested that the 
biochemical defect was a deﬁ  cient MTHFR activ-
ity that is partially responsive to folate therapy.
8338
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Another reason for lowering homocysteine 
concentrations by riboﬂ  avin, vitamin B-12, folate, 
and vitamin B-6 supplementation is the reduction 
of anger and hostility. Positive and signiﬁ  cant 
associations were reported between hostility and 
homocysteine concentrations in both men and 
women and between anger and homocysteine 
concentrations in men.
84
The 677C Æ T polymorphism in MTHFR was 
examined in persons with schizophrenia, major 
depression, and bipolar disorder.
85 The TT variant 
was found in 12% of 419 control subjects, 21% of 
297 patients with schizophrenia (p  0.0006; 
p  0.002 after Bonferroni correction), 28% of 
32 patients with major depression (p  0.06; 
p  0.02 after Bonferroni correction), and 13% of 
40 patients with bipolar disorder (NS). The authors 
pointed out that the oxidation product of homocys-
teine, homocysteic acid, exerts potent excitatory 
effects. An overrepresentation of the TT variant 
has been found in people with schizophrenia who 
responded to neuroleptics compared with that in 
control subjects.
86
In another study, high homocysteine concentra-
tions were found in 9 of 20 patients with 
schizophrenia.
87 The thermolabile 677C Æ T poly-
morphism was screened for in a follow-up study of 
11 patients with high homocysteine concentrations. 
Seven of the 11 patients, 6 males and 1 female, had 
the homozygous TT genotype. One male patient 
was heterozygous and all 3 normal homozygotes 
were females. In the patients who were homozygous 
for the polymorphism, homocysteine concentra-
tions did not respond to vitamin B-12 but were 
normalized by folate supplementation. In the 
healthy homozygotes, however, homocyste-
ine concentrations were reduced by vitamin B-12 
alone. It was concluded that homozygosity for 
thermolabile MTHFR may be a risk factor for 
schizophrenia-like psychosis, and that this risk 
might be reduced by folate supplementation.
88 In a 
small study, homocysteine was signiﬁ  cantly higher 
in patients with schizophrenia who had low serum 
folate concentrations (n = 6) than in control subjects 
with low serum folate concentrations (n = 8).
89
Clinical trials of B vitamin therapy (including 
folate and riboﬂ  avin) in relation to schizophrenia 
and rages are warranted on the basis of the asso-
ciation of higher homocysteine concentrations with 
anger
90 and schizophrenia
91 and the association of 
the TT genotype with schizophrenia. Homocysteine 
accumulation can be an indicator of a defective 
enzyme in the methylation pathway and treatment 
with vitamin precursors of substrates and cofactors 
in that pathway such as riboﬂ  avin, vitamin B-12, 
folate, and vitamin B-6 may be beneﬁ  cial in man-
aging rages and schizophrenia. A UL for folate 
intake from supplements and fortiﬁ  ed foods has 
been set at 1000 μg/d for adults and 300 μg/d for 
2-y-olds increasing to 800 μg/d for 16-y-olds, 
although higher amounts seem warranted in many 
cases.
Vitamins C and E
A case control study was done in 2004 that looked 
at 93 institutionalized subjects (15 of which had 
Alzheimer’s disease and 28 of which had senile 
dementia) and 50 subjects who were mentally 
healthy, all of whom were aged 65+ years. Despite 
having similar dietary intakes of vitamin C, the 
average plasma vitamin C levels were much higher 
in the control group than those who had some form 
or dementia (0.84 mg/dl versus 0.56 mg/dl).
92 
However, vitamin C supplementation has proven 
more effective when taken with vitamin E. As 
vitamin C is oxidized, it appears to regenerate the 
vitamin E, acting as an antioxidant. This in turn 
promotes the oxidation of vitamin E and its ability 
to deactivate other free radicals.
93
The Honolulu-Asia Aging Study is a perfect 
example of this vitamin C-E synergy in which 
3,385 Japanese-American men, ages 71–93, were 
investigated, 386 of which had some kind of 
dementia, Alzheimer’s, or showed cognitive 
difﬁ  culties. This data was obtained in 1982, in 
addition to information about their supplement 
intake/use. They were questioned again in 1988, 
and were ﬁ  nally assessed for dementia and mental 
abilities between 1991 and 1993. Those taking 
vitamins C and E on a regular basis in 1988 were 
88% less likely to have vascular dementia four 
years later. Of those in 1991–93 who still did not 
have any form of dementia, the men that took 
vitamins C and E supplements from 1988 were 
20% more likely to have better cognitive function, 
and those who took the supplements in 1982 and 
1988 had a 75% greater chance of better mental 
performance.
94
A similar study was done from 1995 to 2000, 
where 4,740 men and women (ages 65 and older) 
were assessed in 1995–97 and again in 1998–2000. 
The initial visit found 200 prevalent cases of 
Alzheimer’s, whereas the follow-up visit found 39
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104 new/incident cases. The greatest reduction in 
prevalence and incidence was found in those who 
took vitamins C and E supplements in combination 
with each other, about 78% in prevalence and about 
64% in incidence.
95 Even more interesting is vita-
min E’s abilities to not only help prevent 
Alzheimer’s, but slow the progression of the dis-
ease as well; 341 patients with the disease (of 
about moderate severity) were treated with 2000 
units a day of vitamin E. When compared to a 
placebo group, the patients treated with vitamin 
E showed signiﬁ  cantly less progression of the 
disease at the end of the two year course treat-
ment.
96 Alpha-Tocopherol is the main form of the 
lipid-soluble vitamin E in animal tissues and 
plasma. The DRI for vitamin E is 15 mg/d (× 1.5 
IU/mg = 22.5 IU/d) as α-tocopherol.
97 The UL of 
vitamin E on the basis of supplementation with 
α-tocopherol is 1000 mg/d (1500 IU) as a result 
of adverse effects including increased risk of 
hemorrhage.
98 In 2 patients mentioned above, 
the reinstatement of α-tocopherol treatment 
showed a linear relation to serum α-tocopherol 
concentrations. The maximal dosage (40 mg•kg 
body wt
−1•d
−1) resulted in a plasma concentration 
50 μmol/L.
99
DHEA (dihydroepiandosterone) supplementa-
tion has been shown beneficial for major depres-
sion, especially for women over age 70.
100 
S-Adenosylmethionine (SAMe) is a substance 
found naturally in the human body which serves 
as a methyl donor in many synthetic reactions, 
and may contribute to an increase in the levels 
of certain neurotransmitters when given in 
supplement form. It appears to have enough of 
an antidepressant effect to warrant further 
research.
101,102,103 Other B vitamins have been 
examined for a role in depression as well, in 
particular vitamin B6 and folic acid.
104,105,106,107,
108,109 One third of depressed patients have low 
folic acid levels, with treatment improving their 
depression.
110 Low serum folate and B12 levels 
predict refactory responses to antidepressant 
medication.
111,112,113,114 Inositol is, unofﬁ  cially, a 
B vitamin that is found in cell membranes 
(phosphatidylinositol) where it functions closely 
with choline.
115 Inositol was equivalent to single-
drug therapy for depression and panic disorder in 
one study and is a potential antidepressant.
116,117 
One study found that 75% of depressed patients 
were magnesium deﬁ  cient with another 9% at 
borderline levels.
118 Magnesium supplementation 
was helpful.
119 Melatonin has been reported 
effective with 84% of depressed patients showing 
abnormal levels.
120
Amino acid supplementation has been reported 
helpful in some patients with depression.
121 Tryp-
tophan has long been reported effective for depres-
sion, often in combination with vitamins B3 and 
B6.
122,123
Conclusion
These are just a few examples of how micronutri-
ents can play a beneﬁ  cial role in the treatment of 
several psychiatric illnesses. As researchers 
continue to investigate the efﬁ  cacy of nutritional 
healing, more and more information will be readily 
available to those wishing to take a more natural 
course of therapy. For the time being, we can rely 
on the already thousands of successful studies that 
“alternative therapies” need not be an alternative 
anymore.
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